Literature DB >> 16509830

Protective immunity against hepatitis C virus infection.

Lisa N Elliot1, Andrew R Lloyd, John B Ziegler, Rosemary A Ffrench.   

Abstract

There is increasing evidence that a small percentage of individuals exposed to the hepatitis C virus have the capacity to generate a strong cellular immune response against the virus and avoid persistent infection, and perhaps do so repeatedly after re-exposure. This article reviews the evidence that the responses identified in this unique group of individuals represent the protective immunity that will need to be elicited by hepatitis C virus vaccines.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16509830     DOI： 10.1111/j.1440-1711.2006.01427.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


  12 in total

Review 1.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

2.  Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha.

Authors:  He YingLi; Lin Shumei; Yang Qian; Chen Tianyan; Zhao Yingren; Chen Wei
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

3.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

Review 4.  Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research.

Authors:  J J Weiss; N Bräu; A Stivala; T Swan; D Fishbein
Journal:  Aliment Pharmacol Ther       Date:  2009-03-26       Impact factor: 8.171

5.  Positive deviance control-case life history: a method to develop grounded hypotheses about successful long-term avoidance of infection.

Authors:  Samuel R Friedman; Pedro Mateu-Gelabert; Milagros Sandoval; Holly Hagan; Don C Des Jarlais
Journal:  BMC Public Health       Date:  2008-03-20       Impact factor: 3.295

6.  Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients.

Authors:  Ruzica Lukic; Nevena Gajovic; Ivan Jovanovic; Milena Jurisevic; Zeljko Mijailovic; Veljko Maric; Biljana Popovska Jovicic; Nebojsa Arsenijevic
Journal:  Dis Markers       Date:  2017-04-11       Impact factor: 3.434

7.  Hepatitis C cross-genotype immunity and implications for vaccine development.

Authors:  Nazrul Islam; Mel Krajden; Jean Shoveller; Paul Gustafson; Mark Gilbert; Jason Wong; Mark W Tyndall; Naveed Zafar Janjua
Journal:  Sci Rep       Date:  2017-09-26       Impact factor: 4.379

Review 8.  Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.

Authors:  Julia L Casey; Jordan J Feld; Sonya A MacParland
Journal:  Cells       Date:  2019-04-05       Impact factor: 6.600

9.  Hepatitis C virus infection and spontaneous clearance in HTLV-1 and HIV co-infected patients in Salvador, Bahia, Brazil.

Authors:  Chloe Le Marchand; Fabianna Bahia; Kimberly Page; Carlos Brites
Journal:  Braz J Infect Dis       Date:  2015-08-05       Impact factor: 1.949

10.  A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.

Authors:  Yong-Hong Zhang; Yan Zhao; Ushani S Rajapaksa; Tessa M Lawrence; Yan-Chun Peng; Jinghua Liu; Keyi Xu; Ke Hu; Ling Qin; Ning Liu; Huanqin Sun; Hui-Ping Yan; Emmanouela Repapi; Sarah Rowland-Jones; Robert Thimme; Jane A McKeating; Tao Dong
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.